Loading organizations...
§ Private Profile · 953 Indiana St, San Francisco, California, 94107, United States
Scribe Biosciences is a technology company.
Key people at Scribe Biosciences.
Scribe Therapeutics develops engineered CRISPR-based genetic medicines, utilizing advanced gene editing and epigenetic silencing platforms. The company precisely modifies genes or their expression, creating safe, effective therapeutic solutions. Its proprietary CRISPR systems offer enhanced specificity and delivery, addressing disease root causes and advancing next-generation gene therapies.
The company was founded by CRISPR pioneers from UC Berkeley, including Nobel laureate Jennifer A. Doudna, PhD, Benjamin L. Oakes, PhD, David F. Savage, PhD, and Brett Staahl, PhD. Their insight centered on the transformative potential of engineered CRISPR systems for superior genetic medicines. Benjamin Oakes, as President and CEO, guides scientific breakthroughs into therapeutic applications.
Scribe Therapeutics builds a pipeline for cardiometabolic diseases, collaborating with pharmaceutical partners to broaden therapeutic reach. The company’s vision is to reshape disease treatment by enabling safe, effective, and accessible genetic medicines. Scribe aims to transform human health, delivering lasting impact through its innovative engineered CRISPR technology.
Key people at Scribe Biosciences.
Scribe Biosciences is an early-stage biotechnology company developing single-cell analysis tools using printed droplet microfluidics for picoliter-scale manipulations and fluorescence-activated droplet sorting.[2][4][5] It focuses on accelerating immunotherapy discoveries by enabling precise study of single-cell interactions, particularly for infectious cancer diseases and cell therapy development, serving researchers and clinicians in oncology and immunotherapy.[2][4][5][6] The technology addresses the need for high-throughput, high-precision profiling of immune cell functions, with early traction including $250,000 in funding from BioTools Innovator and a small team of 3-6 employees in San Francisco.[2][4][5] Note that search results distinguish this from Scribe Therapeutics (scribetx.com), a separate CRISPR-focused firm founded later with Nobel-inspired genetic medicines for cardiometabolic disease.[1][3]
Scribe Biosciences was founded in 2017 in San Francisco, California, as an early-stage biotech startup.[2][4][5] Key details on founders are limited in available sources, but the company emerged to pioneer technologies for linked functional and genomic profiling of single-cell interactions, targeting gaps in immunotherapy research.[4][5] Early traction included raising $250,000 from investor BioTools Innovator, supporting development of its droplet microfluidics platform.[2] A pivotal moment was its 2023 feature in MedTech Innovator, highlighting "microenvironment on demand" technology for high-throughput live cell assays in cell therapy.[6] Leadership includes Ian Walton as Senior Vice President of Engineering.[4]
Scribe Biosciences rides the wave of advanced cell therapy and immunotherapy trends, where identifying potent immune cells is critical for effective treatments against cancer and infectious diseases.[6] Timing aligns with surging demand for single-cell technologies, as traditional methods lack the throughput-precision balance needed for scalable cell therapy development amid a global push for personalized medicine.[2][6] Market forces like rising immunotherapy investments and needs for precise functional profiling favor its droplet-based platform, influencing the ecosystem by enabling faster discovery of therapeutic cells and reducing development timelines for biotech firms.[4][5][6]
Scribe Biosciences is poised to scale its microfluidics platform amid booming cell therapy markets, potentially expanding to more immunotherapy applications or partnerships with larger biopharma players. Trends like AI-driven single-cell analysis and precision oncology will shape its path, amplifying its throughput edge. Its influence could grow by setting standards for high-fidelity cell profiling, transforming early discoveries into viable therapies—positioning it as a key enabler in rewriting immunotherapy's story from lab to clinic.
